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Abstract: Iron is a vital trace element for humans, as it plays a crucial role in oxygen transport,
oxidative metabolism, cellular proliferation, and many catalytic reactions. To be beneficial, the amount
of iron in the human body needs to be maintained within the ideal range. Iron metabolism is one of
the most complex processes involving many organs and tissues, the interaction of which is critical
for iron homeostasis. No active mechanism for iron excretion exists. Therefore, the amount of iron
absorbed by the intestine is tightly controlled to balance the daily losses. The bone marrow is the
prime iron consumer in the body, being the site for erythropoiesis, while the reticuloendothelial system
is responsible for iron recycling through erythrocyte phagocytosis. The liver has important synthetic,
storing, and regulatory functions in iron homeostasis. Among the numerous proteins involved
in iron metabolism, hepcidin is a liver-derived peptide hormone, which is the master regulator
of iron metabolism. This hormone acts in many target tissues and regulates systemic iron levels
through a negative feedback mechanism. Hepcidin synthesis is controlled by several factors such
as iron levels, anaemia, infection, inflammation, and erythropoietic activity. In addition to systemic
control, iron balance mechanisms also exist at the cellular level and include the interaction between
iron-regulatory proteins and iron-responsive elements. Genetic and acquired diseases of the tissues
involved in iron metabolism cause a dysregulation of the iron cycle. Consequently, iron deficiency or
excess can result, both of which have detrimental effects on the organism.
Keywords: Iron; metabolism; anemia; hepcidin; disorders
1. Introduction
Iron is the second most abundant metal on earth, comprising about 5% of the earth’s crust [1].
Its significance to humans is paramount, as it is a vital micronutrient for human existence. Being a
d-block transition metal, it interchanges between various oxidation states, which empowers it to
participate in electron transfer and also bind to several biological ligands. The two most common iron
states are the divalent ferrous (Fe2+) and the trivalent ferric (Fe3+). Within the human body, iron is
required as a cofactor for many haemoproteins and non-haem iron-containing proteins. Haemoproteins
include haemoglobin and myoglobin that are responsible for oxygen binding and transport, catalase and
peroxidase enzymes, which take part in oxygen metabolism, and cytochromes, which are involved in
electron transport and mitochondrial respiration. Non-haem iron-containing proteins also have crucial
functions, as these are used in DNA synthesis, cell proliferation and differentiation, gene regulation,
drug metabolism, and steroid synthesis [1].
The total amount of iron in a 70 kg man is about 3500–4000 mg, corresponding to an average
concentration of 50–60 mg of iron per kg of body weight. The vast majority (2300 mg, 65%) of iron in the
Medicines 2019, 6, 85; doi:10.3390/medicines6030085 www.mdpi.com/journal/medicines
Medicines 2019, 6, 85 2 of 15
body is found in the haemoglobin of erythrocytes. About a tenth of total iron (350 mg) is present in the
myoglobin of muscle and enzymes and cytochromes of other tissues. Of the remainder, approximately
500 mg is found in macrophages of the reticuloendothelial system (RES), about 200–1000 mg is stored
in hepatocytes in the form of ferritin, while 150 mg of iron is found in the bone marrow [2,3].
The duodenum plays a very significant role in dietary iron absorption. The absorbed iron can
be stored in the enterocytes or enter the circulation and be transported around the body bound to
the liver-derived plasma protein transferrin (Tf). It is then taken up by tissues and utilised for many
processes, such as erythropoiesis in the bone marrow, myoglobin synthesis in muscle, and oxidative
metabolism in all respiring cells. Splenic, hepatic, and bone marrow macrophages, which belong to the
RES, have the task of recycling iron from senescent erythrocytes. The liver has an important storing
and regulatory function. Through the production of the hormone hepcidin, it controls the release of
iron from enterocytes and macrophages into the circulation. Therefore, this permits the fine regulation
and the maintenance of plasma iron concentrations within physiological levels. Figure 1 presents the
main tissues where iron metabolism occurs.
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Figure 1. The main tissues involved in the regulation of systemic iron metabolism. Duodenal enterocytes
are responsible for dietary iron absorption. Upon absorption, iron circulates around the body bound to
the protein transferrin and is taken up by different tissues for utilisation. The reticuloendothelial system,
which i cludes the splenic macrophages, recycles iron from enescent erythrocyt s. Among many
othe functions, the liver produces the hormone hepcidin. Hepcidin controls the rel ase of iron from
enterocytes and macrophages into the circulation and is regarded as the master regulator of systemic
iron metabolism.
Approximately 1–2 mg of iron is lost daily from the body through enterocyte and skin desquamation
and through haemorrhages and parasitic infestations. No active mechanism of iron excretion exists.
Consequently, a daily quantity of 1–2 mg of intestinal iron absorption is required for iron homeostasis.
This demand is increased in physiological conditions such as growth, pregnancy, and menstruation.
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Meanwhile, about 25 mg of iron is recycled every day by the RES as senescent erythrocytes are
phagocytosed. This means most of human iron homeostasis is dependent on iron recycling [4].
Tight regulation of iron metabolism is imperative for its homeostasis.
This review assesses the roles of the intestine, the bone marrow, the spleen, and the liver in iron
metabolism. Furthermore, a consideration of tissue-specific pathological situations and their effects on
iron homeostasis is presented. Finally, management of these iron-associated disorders is included.
2. Intestine
An average western-world diet includes the ingestion of about 15–20 mg of iron, 10% of which is
present in the haem form and the remainder in the non-haem/ionic form. Only about a tenth of the
consumed iron is absorbed, predominantly within the duodenum and lesser amounts in the jejunum [2].
Most of the ingested haem-iron is found in haemoglobin and myoglobin of meat proteins. The low
gastric pH releases these proteins from meat, and subsequent protease action in the stomach and the
intestine releases free haem [5]. It has been proposed that enterocytes absorb haem via the Haem
Carrier Protein 1 transporter (HCP1) localised on their brush-border membrane [6]. Evidence from a
later study showed that this protein is a proton-coupled folate transporter (PCFT), and therefore the
acronym PCFT/HCP1 is sometimes used for the transporter [7]. Once haem enters the enterocyte, it can
be degraded via the action of haem oxygenase (HO-1) to release free iron, which joins the intracellular
labile iron pool (LIP), as depicted in Figure 2. Moreover, intact haem may also be absorbed into the
circulation via two exporter proteins found on the enterocyte basolateral membrane: the breast cancer
resistant protein (BCRP) and the feline leukaemia virus subgroup C (FLVCR) [8].
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Figure 2. In the enterocytes, haem can be degraded to free iron, which enters the intracellular labile
iron pool.
Non-haem iron is found in meat and plant foods and largely exists in the ferric (Fe3+) form.
Ferric iron, unlike ferrous (Fe2+) iron, is highly insoluble and not easily absorbed. Its reduction to
ferrous iron is essential, since the latter is the preferred form for absorption. The low pH created in
the stomach, as well as the presence of dietary ascorbic acid (vitamin C), reduce Fe3+ to Fe2+ ions,
enhancing solubility and absorption [9]. The relatively more acidic environment in the duodenum and
the proximal jejunum compared to more distal intestinal segments explains why iron absorption occurs
proximally within the gastrointestinal tract. Very importantly, the duodenal cytochrome b (Dcytb)
protein is localised on the brush-border membrane of the enterocytes. Dcytb is a ferrireductase enzyme
responsible for the reduction of Fe3+ to Fe2+ ions [10]. It accepts electrons intracellularly from the
oxidation of ascorbic acid into dehydroascorbic acid and uses these to catalyse the reduction of ferric to
Medicines 2019, 6, 85 4 of 15
ferrous iron (Figure 3), thus portraying one way in which ascorbic acid is involved in iron absorption [11].
Following this reduction process, divalent Fe2+ ions are transported into the duodenal enterocytes via
the divalent metal transporter 1 (DMT1). DMT1 is another duodenal brush-border membrane protein,
which transports several divalent metal ions across the membrane, including ferrous iron, zinc(II),
and copper(II) [12]. This transport is proton(H+)-coupled and depends on the presence of luminal H+
ions. This is accomplished by another brush-border membrane transporter, the Sodium/Hydrogen
Exchanger (NHE), which allows proton recycling across the duodenal luminal membrane.
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Figure 3. Low stomach pH and dietary ascorbic acid reduces non-haem iron from the highly insoluble
Fe3+ form to Fe2+, which is more readily absorbed. Duodenal cytochrome b accepts electrons
intracellularly from oxidation of ascorbic acid into dehydroascorbic acid and uses these to catalyse the
reduction of Fe3+ to Fe2+.
Once absorbed, ferrous iron joins the intracellular LIP, and it is postulated that this free and
highly reactive ion is chelated by low-molecular-weight organic acids, amino acids, and proteins [9].
When there is a low demand for iron in the body, absorbed iron is stored within the enterocyte in the
form of ferritin, an intracellular iron storage protein. Ferritin is made up of heavy and light chain
subunits, which create a spherical hollow space that can accommodate up to 4500 iron ions. Enterocytes
have a short life expectancy, as they are desquamated and replaced every few days. Consequently,
iron stored in ferritin is lost upon enterocyte desquamation [9]. On the contrary, when iron demand is
high, the absorbed ferrous iron is transported across the basolateral membrane into blood. This phase
is controlled by ferroportin 1 (FPN1), a ferrous iron export protein that modulates how much of the
enterocyte iron is absorbed into circulation and made available to the body [13]. For this reason,
FPN1 expression is tightly regulated by the hepatic hormone hepcidin.
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Oxidation of the absorbed ferrous iron back to ferric iron is required for transport by the plasma
protein Tf. This is achieved by hephaestin (HEPH), a multi-copper ferroxidase enzyme anchored to the
basolateral enterocyte membrane and coupled to FPN1, which catalyses the oxidation of Fe2+ to Fe3+
ions [14]. Additionally, there is ceruloplasmin, a circulating copper-carrying protein synthesised in the
liver, which also exhibits ferroxidase activity [15]. Fe3+ then binds to Tf, which has a high affinity for
Fe(III) and enables iron transport around the body (Figure 4). Apotransferrin (apo-Tf) is the unbound
form of this transporter and contains two ferric binding sites, of which none, one, or both may be filled.
Under physiological conditions, only about 30% of Tf is saturated. This has an important buffering
function that prevents any sudden build-up of non-transferrin-bound iron (NTBI), which, being highly
reactive, may cause oxidative injury if taken up by the tissues [1].
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Intestine-Related Iron Metabolism Disorders
Several physiological abnormalities of the intestines interfere with iron metabolism. Some are
related to increased iron loss from the gastrointestinal tract. Increased gastrointestinal bleeding creates
an iron deficit through blood loss and leads to iron-deficiency anaemia. Intestinal haemorrhage can be a
result of gastric or duodenal ulcers eroding into blood vessels or due to the presence of a gastric cancer.
Inflammatory bowel disease also causes bleeding and subsequent iron loss. In the distal segment
of the alimentary tract, haemorrhages can arise due to colonic cancer or haemorrhoids. Proximally,
oesophageal varices, oesophagitis, and oesophageal cancer are other causes of blood loss. Moreover,
hookworm infection, which affects hundreds of millions of people worldwide, is another cause of
iron-deficiency anaemia. These worms parasitize the gut for many years, extravasating 0.3–0.5 mL of
blood from the intestinal mucosa every day [16].
Iron malabsorption is another broad category of deviations from normal intestinal iron metabolism.
This arises from total or partial gastrectomy, where reduced gastric acid production results in a more
alkaline luminal environment that does not favour iron absorption. Iron malabsorption can also be a
consequence of coeliac disease, in which villous atrophy reduces the intestinal mucosal surface area
available for absorption. Similarly, Crohn’s disease is another malabsorption syndrome. Furthermore,
infection by helicobacter pylori causes gastric atrophy, which reduces iron absorption [17]. Moreover,
this infection can incite gastric and duodenal ulcers with subsequent blood and iron loss. Finally,
some drugs, for example, proton-pump inhibitors and anti-acid agents associated with increased pH,
interfere with iron absorption by reducing intestinal uptake of the nutrient [18].
3. Bone Marrow
As already mentioned, the amount of iron in haemoglobin accounts for about two thirds of the
mass of iron in the human body. The bone marrow is thus the prime iron consumer in the body, since
this is where erythropoiesis takes place. Almost all nucleated cells in the body express transferrin
receptors (TfR1) on their plasma membrane, which have a high affinity for iron-bound transferrin.
There is a correlation between TfR1 levels and cellular iron requirements. This receptor is highly
expressed in erythroblasts but to a lesser extent in hepatocytes [19]. The receptor is a disulphide-linked
transmembrane glycoprotein, which forms a homodimer, and as each of its two subunits can bind one
Tf molecule, a total of two Tf molecules can be bound by each TfR1 [20]. Factors such as temperature
or energy do not affect the efficiency of the interaction between Tf and TfR1. The factor that affects this
interaction is the iron content of the Tf molecule. The affinity of interaction increases with increasing
number of Fe3+ ions bound to Tf. Therefore, diferric Tf (Fe2Tf) has the greatest affinity for TfR1,
monoferric Tf (Fe1Tf) has an intermediate affinity, while apo-Tf expresses the lowest affinity for TfR1 [1].
An important property of TfR1 is that at an extracellular pH (7.4), when it binds to Fe2Tf, it reduces the
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accessibility of the latter to iron acceptors and consequently diminishes the possibility for nonspecific
iron release from Fe2Tf at the cell membrane [21].
Transferrin-bound iron (TBI) enters the cell via receptor-mediated endocytosis. Initially,
iron-bound transferrin binds to TfR1 at the cell membrane, leading to the production of the
iron-transferrin/transferrin receptor (Fe2Tf-TfR1) complex [22]. Consequently, energy-dependent
endocytosis of Fe2Tf-TfR1 complexes occurs as the cell membrane becomes surrounded by clathrin
proteins. These proteins cause the invagination of the cell membrane containing the Tf-TfR1 complexes
and the formation of clathrin-coated endosomes [23]. Subsequently, clathrin proteins are removed, and
the endosomal contents are rendered acidic due to proton influx via an ATP-dependent proton pump
at the endosomal membrane. The resultant low pH causes conformational changes in both Tf and
TfR1, which promotes the dissociation of iron from the Tf-TfR1 complex. However, apo-Tf still remains
bound to TfR1, since at this low pH (≤5.5), apo-Tf binds to TfR1 with the same affinity as Fe2Tf does
at pH 7.0 [24]. The released Fe3+ ions undergo reduction to Fe2+ by the ferrireductase STEAP3 (six
transmembrane epithelial antigen of prostate) protein, which belongs to the metalloreductase family [25].
Ferrous iron is transported out of the endosome via DMT1 and becomes available for either direct
use or storage in ferritin. Finally, the apo-Tf-TfR1 complex is transferred back to the cell membrane,
where the extracellular pH (7.4) reduces the affinity of apo-Tf for TfR1, causing dissociation and the
release of apo-Tf back into the circulation [24]. Hence, both molecules are recycled. Recent findings
reveal evidence that TfR2 mediates lysosomal delivery of transferrin in erythroid progenitors that
TfR2 may also contribute to mitochondrial iron delivery [26]. Hence, TfR2 null donor cells manifest
microcytic red cells and abnormal hemoglobinization in mouse marrow transplant models [27].
Erythropoiesis begins in the bone marrow once pluripotent stem cells differentiate into erythroid
precursor cells in the presence of the hormone erythropoietin. However, haemoglobin synthesis is
only initiated when the erythroid precursor cells start to differentiate into erythroblasts, expressing
transferrin receptors at this stage and taking up iron. The first and the final steps of haem synthesis
occur in the mitochondrion, while the intermediate steps take place in the cytoplasm. The first step,
which is essentially rate-limiting, involves the conversion of glycine and succinyl coenzyme A to
δ-aminolaevulinic acid (ALA) catalysed by the enzyme ALA synthase. Pyridoxine (vitamin B6) is the
coenzyme for this reaction and is stimulated by erythropoietin and inhibited by haem. The laevulinate
product is exported into the cytoplasm, and the condensation of two ALA molecules forms a
monopyrrole pyrrole ring (porphobilinogen) (PBG) by a condensation reaction. Four molecules of PBG
form hydroxymethylbilane (HMB) tetrapyrrole macrocycle, which cyclizes to form uroporphyrinogen
III. The next step is the modification of the acetate side chains. The decarboxylation reactions produce
coproporphyrinogen, which enters the mitochondrion to be converted into porphyrinogen IX, i.e., the
sequential oxidative decarboxylation of the two propionate groups of pyrrole rings to two vinyl
groups. The final step in the haem biosynthetic pathway is the oxidation of porphyrinogen IX to
protoporphyrin IX (Figure 5). Meanwhile, mitoferrin-1, an iron transporter, facilitates iron entry into
the mitochondrion [28]. By interacting with the ATP-binding cassette transporter ABCB10, mitoferrin-1
binds to mitochondrial ferrochelatase to form an oligomeric complex [29]. Ferrochelatase catalyses
the final step of this synthetic reaction by inserting iron into protoporphyrin IX to produce haem.
Subsequently, haem is exported into the cytosol via mitochondrial haem exporters and combines
with globin chains formed on ribosomes to generate haemoglobin. With repeated cellular divisions,
the nucleus condenses and is eventually lost, thus resulting in a reticulocyte. Ultimately, the remaining
RNA is also lost from the circulating reticulocytes, which mature into erythrocytes.
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Figure 5. Haem synthesis. Haem synthesis is a complex multistep reaction whose first and final steps
occur in the mitochondrion, while the intermediate steps take place in the cytoplasm. Iron is imported
into the mitochondrion and inserted into protoporphyrin IX to produce haem. Subsequently, haem
is exported into the cytosol, where it combines with α and β globin chains formed on ribosomes to
create haemoglobin.
Irrespective of the cell type, the mitochondrion is the organelle consuming the most iron
intracellularly. It is a central player in the regulation of cellular iron metabolis . Most of the iron
taken up by a cell is imported into the mitochondrion for the synthesis not only of haem but also
of iron-sulphur clusters (ISCs). These are cofactors made up of iron cations and sulphide anions.
They bind to scaffold proteins and then get targeted to particular proteins [1]. Iron is indeed a vital
cofactor in complexes I–IV of the mitochondrial respiratory chain. On the one hand, complexes I–III
are enzymes that contain ISCs, whilst on the other hand, complexes III and IV contain haem iron.
Bone Marrow-Related Iron Metabolism Disorders
Iron-loading anaemias include a mixture of inherited and acquired anaemias, which are
characterized by ineffect ve erythropoies s, low hepcidin levels, excessive iron absorption, and
secondary iron overload [30]. Abnormal erythropoiesis causes ana mia, leading to a excessive increase
in iron bsorption and resulting in ir n overload. Sideroblastic anaemia, cong nital dyserythropoietic
a a mias, and low-grade myelo ysplas ic syndromes ar a few examples of iro -loading a a mi s
ue to ineffective erythropoiesis.
In siderobl tic anaemias, hypochromic c lls can be seen in the peripheral blood, while excess
iron a d ring sideroblasts can be observed in the bone marrow, the latter being the diagnost c f ature
of sideroblastic anaemia. Iron accumulates in the mitoch ndria of erythroblasts due t abnormal
haem synthes s. This creates a ring of iron granules ar und the nucl us. Sideroblastic anaemia can
be inherited a an X-linked disease. O e form of this disorder involves a structur l d fect in th
e zym ALA synthase, which catalyses the first step in haem synthesis. Acquired causes i clud
myelod spl ia, myeloproliferative disorders, myeloid leukaemia, drugs such as isoniazid, al ohol
isuse, and lead toxicity. Sideroblastic anae ia can also be secondary to rheumatoid arthritis,
carcinomas, and megaloblastic and haemolytic anaemias [8].
4. Spleen
As the lifespan of an erythrocyte is approximately 120 days, the bone marrow produces over
200 billion new erythrocytes daily, involving about 24 mg of iron for haem synthesis and erythropoiesis.
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Daily intestinal iron absorption of 1–2 mg is simply not enough to meet this demand for 24 mg,
as this only balances iron loss. Instead, this requirement is mostly met through iron recycling by
RES macrophages phagocytosing senescent erythrocytes. Indeed, approximately 80% of plasma iron
follows the route from the RES to the bone marrow. The spleen is the major site for iron recycling with
some contribution from the liver and the bone marrow. A further function of the RES is the storage of
iron during periods of iron excess [31].
Senescent erythrocytes exhibit markers of ageing, such as a decrease in membrane flexibility and
the presentation of phosphatidylserine on their cell membrane [32]. These changes are recognised by
the splenic macrophages triggering erythrocyte phagocytosis. Following phagocytosis, the erythrocytes
are included in a phagolysosome and degraded by hydrolytic enzymes and reactive oxygen species to
release their haem. Thereafter, the enzyme HO-1, in the presence of oxygen, catalyses the breakdown
of haem into iron(II), carbon monoxide, and biliverdin [33]. Subsequently, Fe2+ ions are transported
out of the phagolysosome via the natural resistance-associated macrophage protein-1 (NRAMP1) and
enter the cytoplasm to join the LIP [34]. NRAMP1 is a hydrophobic protein present only in monocytes
and macrophages and has a 64% amino acid sequence identity with DMT1, also known as NRAMP2.
Apart from iron uptake through erythrophagocytosis, the splenic and other macrophages of the
RES also obtain iron via other processes. Normally, there is some erythrocyte destruction occurring
within the vasculature. This releases haemoglobin into the plasma, which immediately binds to the
plasma protein haptoglobin. Upon binding, a haemoglobin–haptoglobin complex is formed, and
this inhibits the oxidative activity of haemoglobin. Monocytes and macrophages, and particularly
splenic and hepatic ones, exclusively express the CD163 protein receptor. This receptor recognises
the haemoglobin–haptoglobin complex and binds to it with high affinity. Then, CD163-mediated
endocytosis of the complex takes place, and its degradation follows within the macrophage releasing
haemoglobin [35]. In certain cases of augmented haemolysis, such as haemolytic anaemia and
thalassaemia, haptoglobin may become saturated with haemoglobin, resulting in free haemoglobin in
the circulation. Some of this breaks down to give haem, which then binds to hemopexin, a plasma
glycoprotein, to produce a haem–hemopexin complex. A wide range of cell types, including
macrophages, possess the low-density lipoprotein receptor-related protein LRP/CD91 that serves as a
receptor for the haem–hemopexin complex and causes its endocytosis to further contribute to iron
recycling [36]. Finally, macrophages can also obtain iron from bacteria from the circulation via DMT1,
as well as TBI via TfR1 [2].
Iron is exported from the macrophage and into the circulation via FPN1, the same iron(II)
exporter found in the duodenal enterocyte. Similarly, iron export from macrophages is also subject
to regulation by hepcidin, which controls iron recycling. Exported ferrous iron then undergoes
oxidation by ceruloplasmin to become ferric iron, which binds to apo-Tf and becomes recirculated.
Iron in the cytoplasm of macrophages can also be stored in ferritin. Haemosiderin is an insoluble iron
store that results from the partial digestion of ferritin in lysosomes. Under physiological conditions,
haemosiderin accounts for a very small percentage of the total body iron quantity and is primarily
found in macrophages. As cellular iron content increases, a greater fraction of iron gets deposited into
haemosiderin. When there is an excess of iron, this surplus is diverted into haemosiderin and enables
the cell to store a greater quantity of iron per unit cellular volume. During iron overload, there is
a significant increase in the amount of haemosiderin in macrophages. This has an important safety
aspect, as this form of iron storage in macrophages prevents oxidative damage [2,31].
Spleen-Related Iron Metabolism Disorders
In cases of genetic anaemias and inability of the bone marrow to carry out erythropoiesis, regular
blood transfusions may be the only option for treatment. The transfused erythrocytes are phagocytosed
by splenic and other RES macrophages, and resultant degradation releases iron, which gets recycled
into the bloodstream. With repeated transfusions and erythrophagocytosis, the spleen and other tissues
of the RES secrete a very large amount of iron into circulation, leading to a state of iron overload.
Medicines 2019, 6, 85 9 of 15
The iron-binding capacity of Tf becomes saturated, and this results in the presence of free NTBI in the
plasma which, through the production of reactive oxygen species, causes organ dysfunction.
Hereditary haemochromatosis and anaemia of chronic disease are two conditions where iron
metabolism is disturbed in various tissues, including the spleen and the intestine. Both are related
to abnormalities in hepcidin levels, the pathophysiology of which is discussed in greater detail in
Section 5. In essence, hepcidin downregulates FPN1 and reduces iron export from tissues such as
the RES and the intestine. In hereditary haemochromatosis with low hepcidin levels, there is an
upregulation of FPN1, which results in an increased transport of iron into the blood from the RES
macrophages and intestinal iron absorption. On the contrary, in anaemia of chronic disease, hepcidin
levels are significantly raised. FPN1 downregulation causes reduced intestinal iron absorption, as well
as impaired iron release from macrophages of the spleen and liver.
5. Liver
The liver has a central and critical role in iron homeostasis, as it synthesises many of the proteins
involved in iron metabolism. Above all, the liver is the major site of synthesis of hepcidin, a master
regulator of iron homeostasis [37,38]. Hepcidin expression also occurs on a smaller scale in other tissues,
such as alveolar macrophages, pancreatic β-cells, and the kidneys [39,40]. Expression of the HAMP
gene results in the production of hepcidin preproprotein. This preproprotein undergoes intracellular
proteolytic cleavage by the enzyme prohormone convertase furin to yield the active 25 amino-acid-long
peptide hormone hepcidin [41].
Hepcidin is the main negative regulator of iron homeostasis. It acts by binding to FPN1 to
induce its ubiquitination. Subsequently, the internalisation and lysosomal degradation of FPN1
takes place [42,43]. This down-regulation of FPN1 occurs at the basolateral membrane of duodenal
enterocytes, as well as from the plasma membrane of RES macrophages, hepatocytes, and the placenta.
In the case of the intestine, this means that iron is blocked inside the enterocytes, and thus less can be
absorbed into the circulation, while more iron is lost through enterocyte desquamation. With regards
to the RES, the iron taken up into the macrophages through erythrophagocytosis stays trapped inside
the cells, since its release into the bloodstream by FPN1 is inhibited. Under physiological conditions,
the expression of hepcidin is tightly regulated in order to maintain normal body iron levels. In cases of
increased iron levels, hepcidin synthesis is augmented in an effort to reduce intestinal iron absorption,
as well as to reduce the release of iron from macrophages of the RES into the bloodstream and thus
bring iron levels down to normal. In contrast, when there is iron deficiency, hepcidin production
decreases, and this results in increased intestinal iron absorption, as well as increased iron release from
the RES, which increases the quantity of iron in the circulation. Similarly, in conditions of anaemia and
increased erythropoietic activity, hepcidin expression is suppressed, which increases systemic iron
levels [1].
Numerous proteins found on the hepatocellular membrane are considered to act as sensors
of iron levels and control the quantity of hepcidin synthesis. These include haemojuvelin (HJV),
haemochromatosis protein (HFE), TfR1, and transferrin receptor 2 (TfR2). One pathway that regulates
HAMP expression and hepcidin production is the HJV–bone morphogenic protein (BMP) axis. On
the hepatocellular membrane, BMP receptors (BMPRs) are found, whilst HJV acts as a co-receptor for
BMPs. When BMPs bind to the BMPR–HJV complex, the receptor complex becomes activated and
induces the phosphorylation of cytosolic small-mothers-against-decapentaplegic proteins (SMADs) 1,
5, and 8 [44]. These can then bind to SMAD4, and the resulting complex enters the nucleus, where
it binds to BMP-responsive elements on the HAMP promoter [45]. This results in the transcription
of HAMP and subsequent hepcidin synthesis. BMP6 is one of the BMPs involved in this pathway,
and its production takes place in non-parenchymal hepatic cells, such as sinusoidal endothelial cells,
hepatic stellate cells, and Kupffer macrophage cells. When body iron levels increase, BMP6 synthesis
in the non-parenchymal hepatic cells increases [46]. Consequently, more BMP6 binds to the BMPR-HJV
complex, and more hepcidin is synthesised in the hepatocytes.
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Apart from the HJV–BMP axis pathway, a different pathway for the regulation of hepcidin
synthesis is thought to exist, and this includes the HFE and the TfR2 proteins. Normally, HFE is bound
to TfR1 on the hepatocellular membrane [47] at a binding site overlapping with that for Fe2Tf. TfR1
expresses a greater affinity for Fe2Tf than HFE, whilst its affinity for HFE is higher than for apo-Tf.
As iron levels in the blood increase, the quantity of Fe2Tf increases. As more Fe2Tf binds to TfR1,
HFE becomes displaced from TfR1 and associates with TfR2. The Fe2Tf–TfR2–HFE complex then
induces HAMP expression via the extracellular signal-regulated kinase/mitogen-activated protein
kinase (ERK/MAPK) pathway [48]. Some studies suggest that HFE and TfR2 may act independently
of each other in regulating hepcidin synthesis [49,50]. Nonetheless, HFE has been shown to interact
with BMPR ALK3. This interaction inhibits ALK3 ubiquitination and proteasomal degradation and
favours its stabilisation on the hepatocellular membrane. Moreover, HFE increases ALK3 cell-surface
expression. All these demonstrate that HFE can regulate hepcidin synthesis via the BMP pathway [51].
Infection and inflammation trigger an increase in hepcidin synthesis, which serves an important
protective function. The reduction in iron levels reduces the growth of iron-dependent micro-organisms
and helps to eliminate the infection more rapidly. Exposure of the immune system to pathogens
stimulates the release of pro-inflammatory cytokines. One of these is interleukin-6 (IL-6). IL-6 is
recognised by receptors on the hepatocellular membrane, and this interaction activates Janus kinases,
which phosphorylate signal transducers and activators of transcription (STAT) proteins, mainly STAT3.
Phosphorylated STAT3 then enters the nucleus, where it binds to HAMP promoter to stimulate HAMP
transcription and subsequent hepcidin production [52]. In the short term, this inflammatory response
is beneficial to the organism. However, when inflammation persists, the results can be detrimental.
In conditions such as chronic infections, inflammatory diseases, and some malignancies, hepcidin levels
remain constantly elevated. This causes a prolonged reduction in intestinal iron absorption, as well
as sequestration of iron in RES macrophages. Moreover, in response to inflammation, macrophages
synthesise small amounts of hepcidin, which targets FPN1 in an autocrine mode, promoting iron
retention within the macrophages [53]. Therefore, less iron is available for bone marrow utilisation,
resulting in anaemia of chronic disease. Detailed descriptions of the regulatory mechanisms of hepcidin
gene expression in the hepatocyte are reviewed elsewhere [54]. The liver is also an important iron
storing organ. It takes up iron from the circulation in the form of TBI via TfR1 and TfR2, NTBI, ferritin,
haemoglobin–haptoglobin complexes, and haem–haemopexin complexes for storage. Hepatocytes
such as duodenal enterocytes and RES macrophages also possess FPN1 on their plasma membrane,
which enables iron eﬄux from the cell [2]. When there is iron homeostasis, excess iron is stored
in hepatocytes in the form of ferritin; however, when iron overload occurs, more iron is stored as
haemosiderin. In the case of persistent iron overload, high concentrations of ferritin and haemosiderin
accumulate. Lysosomal degradation of ferritin and haemosiderin with reduction of Fe3+ produces
a high lysosomal Fe2+ concentration. Hydrogen peroxide, which is physiologically produced in the
cell, is able to pass through biological membranes. It can also pass into the lysosomal compartment,
where, if a high Fe2+ concentration exists, it will be metabolised via Fenton’s reaction to produce a large
quantity of extremely reactive hydroxyl radicals [55]. These radicals can cause lysosomal membrane
rupture and, upon their release into the cytoplasm, they can cause hepatocellular damage and necrosis
(Figure 6). Consequently, in persistent iron overload states, the liver, being a major iron store, is under
the risk of cirrhosis or hepatocellular carcinoma in the longer term [56].
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Cellular iron balance mechanisms also exist for the control of the stability and the translation
of specific iron-related messenger ribonucleic acids (mRNAs) that code for ferritin, transferrin, TfR1,
DMT1, and ALA synthase. Cytoplasmic iron-regulatory proteins (IRPs) bind to specific iron-responsive
elements (IREs) on these mRNAs and determine whether these undergo translation or not. IRP–IRE
interaction promotes the stability and the translation of the mRNAs for transferrin, TfR1, DMT1, and
ALA synthase. However, in the case of ferritin mRNA, IRP–IRE interaction inhibits its translation and
ferritin synthesis. In iron deficiency, IRPs bind to target mRNA-IREs, and this interaction increases the
synthesis of all the aforementioned proteins, except ferritin, whose synthesis is decreased. This leads
to increased intestinal iron absorption via DMT1. Moreover, the increase in transferrin and TfR1
promotes cellular uptake of iron from the circulation, while the decrease in ferritin prevents iron
storage. Overall, these changes enable i creased cellular utilisation of iron. In contrast, when there
is excess cellular iron, the binding capacity of IRPs for IREs is lost. This causes mRNA degradation
and diminished synthesis of the above-mentioned proteins, although ferritin-mRNA stabilisation and
enha ced ferriti production occur. Consequently, this reduces intestinal iron absorption, decreases
further TfR1-mediated iron inter alisation, and favours the storage of excess intracellular iron into
ferritin [1].
Liver-Related Iron Metabolism Disorders
Primary or hereditary haemochromatosis (HH) is a disease characterised by iron overload and
disproportionately low hepcidin levels. Many types of HH exist; type I results from mutations in
HFE gene, type IIa is due to HJV gene mutations, and type III is due to TfR2 gene mutations. In all
these cases, the liver synthesises less hepcidin, resulting in high ferroportin levels. This leads to
increased intestinal iron absorption, low iron levels in RES macrophages, transferrin saturation, and
the appearance of reactive NTBI in blood. Hepatic iron overload occurs, and, as previously mentioned,
the liver is vulnerable in this state to damage, necrosis, and fibrosis [18]. There is also HH type IV
ferroportin disease, which is an autosomal dominant hereditary iron loading disorder associated with
heterozygote mutations of the ferroportin-1 (FPN) gene.
Secondary haemochromatosis is characterised by iron overload secondary to other medical
conditions. For example, thalassaemia major and aplastic anaemia are conditions that require chronic
transfusion therapies. Repeated transfusions lead to iron overload, and excessive iron storage can
cause damage in iron-storing organs such as the liver and the heart. Furthermore, chronic liver disease
due to alcoholism or viral hepatitis can impair hepatic hepcidin synthesis. The decreased hepcidin
levels promote enhanced intestinal iron absorption, which leads to iron overload that can cause further
hepatic damage [2].
6. Management
Table 1 presents some iron metabolism disorders, the common features associated with them,
as well as how these disorders are managed [8,18].
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Table 1. Management of some disorders and diseases associated with iron.
Disorder Features and Symptoms Management
Peptic ulcers
Abdominal pain, nausea, vomiting, loss of
appetite, weight loss, gastric/duodenal
bleeding, anaemia.
Treatment of the underlying condition; iron
supplementation; blood transfusion in
severe cases.
Inflammatory Bowel Disease
Diarrhoea, low-grade fever, abdominal pain,
blood in the stool, reduced appetite, weight
loss, anaemia.
Corticosteroids, immunosuppressants.
Hookworm infection Abdominal pain, fever, nausea, blood in thestool, anaemia.
Antihelminthic drugs (mebendazole);
iron supplementation if anaemic.
Malabsorption syndromes Diarrhoea, steatorrhoea, weight loss andfatigue, oedema, anaemia.
Gluten-free diet;
iron and vitamin supplementation.
Thalassaemia syndromes
Skin pallor, jaundice, slowed growth,
splenomegaly, facial bone deformities;
transfusion-dependent iron overload.
Blood transfusions;
iron chelation (deferoxamine, deferasirox)
for secondary haemochromatosis;
folic acid supplementation.
Sickle cell anaemia
Sickle cell crisis (abdominal pain, bone pain);
anaemia; pallor, jaundice, hepatomegaly,
splenomegaly in children followed by splenic
infarction later, chronic leg ulcers; prone to
pneumococcal septicaemia.
Prophylactic management (avoid
precipitating factors);
folic acid supplementation;
in case of crisis: rehydration, antibiotics,
and bicarbonate if acidotic;
blood transfusion only if severe anaemia.
Sideroblastic anaemia Skin pallor, fatigue, dizziness, splenomegaly;transfusion-dependent iron overload.
High-dose pyridoxine, folic acid
supplementation, blood transfusion if
severe anaemia;
iron chelation (deferoxamine) if
transfusion-related iron overload.
Anaemia of chronic disease Tiredness, weakness, dyspnoea, skin pallor,dizziness.
Treatment of underlying cause if possible;
iron supplementation is not beneficial;
blood transfusion in severe anaemia.
Haemochromatosis
Joint pain, abdominal pain, fatigue, weakness,
impotence;
cirrhosis, diabetes mellitus, skin
hyperpigmentation, heart failure.
Therapeutic phlebotomy;
iron chelation therapy.
7. Conclusions
Iron is an essential micronutrient for humans, as it is required in several vital biological processes.
The fact that no active mechanism of iron excretion exists highlights the significance of this metal and
possibly suggests that prehistoric humans did not have a constant, adequate iron intake. Iron metabolism
is one of the most complex processes in the human body, involving many organs and tissues, such as
the intestine, the bone marrow, the spleen, and the liver. Maintenance of iron homeostasis is under
the influence of many proteins, with hepcidin being the key regulator. This liver-derived hormone
regulates systemic iron levels through a negative feedback mechanism, and its synthesis is controlled by
factors such as iron levels, anaemia, infection, inflammation, and erythropoietic activity. Cellular iron
balance mechanisms also exist, and these include the interaction between IRPs and IREs. Physiological
disorders within the different tissues involved in iron metabolism interfere with the mechanisms
regulating iron homeostasis. These can ultimately result in iron deficiency or excess, both of which
have detrimental effects on the organism. Labile iron and inflammatory conditions during infection
may generate high levels of toxic free radicals and oxidative stress that can trigger cellular damage and
cause diseases in different tissues and organs. Nowadays, research is increasingly dedicated in the
field of iron metabolism, but countless questions remain unanswered. An increased knowledge of the
physiology of iron homeostasis will facilitate understanding of the pathology of iron disorders and
help improve treatment
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